C4 Therapeutics(US:CCCC) Globenewswire·2026-01-14 12:00Core Insights - C4 Therapeutics is advancing cemsidomide as a foundational medicine for multiple myeloma, with trials set to initiate in 2026 [2][11] - The company is focusing on a new discovery strategy targeting inflammation and neuro-degenerative diseases, leveraging its expertise in targeted protein degradation [2][13] - C4 Therapeutics has a strong financial position, with a cash runway extending to the end of 2028, allowing for continued development through key milestones [2][12] Group 1: Cemsidomide Development - The Phase 2 MOMENTUM trial of cemsidomide is scheduled to begin in Q1 2026, with a recommended dose of 100 µg [1][11] - The Phase 1b trial in combination with elranatamab is set to start in Q2 2026, with ongoing updates expected throughout the trial [1][14] - Initial overall response rate data from the MOMENTUM trial is anticipated in 2H 2027, with efficacy and safety data to follow in mid-2028 [6][11] Group 2: Early Portfolio and Discovery Strategy - C4 Therapeutics aims to deliver up to three investigational new drug applications by the end of 2028, focusing on inflammation and neuro-degenerative diseases [7][13] - The company is utilizing data from the Phase 1 trial of CFT8919 to inform clinical development outside of China [5] - The internal discovery strategy is designed to develop degrader medicines targeting novel pathways, enhancing efficacy for patients with unmet needs [13] Group 3: Financial Position and Strategic Milestones - C4 Therapeutics has completed enrollment in the Phase 1 trial of cemsidomide and dexamethasone, showing promising overall response rates of 40% and 53% at the highest doses [12] - The company has developed a regulatory path for potential accelerated approvals for cemsidomide in multiple treatment lines [12] - Collaborations with major pharmaceutical companies are expected to yield additional research milestones and potential licensing fees [12]